BioCryst reports $9M net loss for 1Q - Birmingham Business Journal:

ignatiywulyxura.blogspot.com
The Birmingham-based biotech firm reported net lossedsof $9.3 million for the three months ended Marchb 31, 2009, compared to the same time in according to Securities and Exchang Commission filings. BioCryst’s net losses for the firsrt quarter of 2008were $13.1 BioCryst slashed its expenses by $11 million year-over-yeart through the first while its research and development revenues fell by $6.4 million durinfg that time. The company attributed the loss to a reductiob in revenue from the contract with the federal government for the developmen of its experimental fludrug peramivir.
The Universith of Alabama at Birmingham spinoff coulsd benefit from the recent swing flu It reported the federal government has asked BioCrysft to prepare a portion of its inventory of peramivir to add tothe U.S. Centerx for Disease Control and Prevention’s strategiv national stockpile. The federalk government wants enough peramivir totreat 1,000 patientzs upon request. Intravenous peramivir is currently undergoinga pre-emergencg use authorization review, accordin to a news release. Government agencies are consideringg using peramivir in the event of a severs influenza outbreak with significant Peramivir is in clinical development unded terms ofa $102.
6 million, four-yeae contract from the U.S. Department of Health and Human BioCryst CEO Jon Stonehouse said his firm is negotiatinhg with the Division of Microbiologyu and Infectious Diseases and the National Institute of Allergy and Infectiouxs Diseases at the National Institutes of Health to studyy the affects of peramivir in pediatric Peramivir has shown some positive signs for the treatment of swiner flu in clinical the newsrelease said.